An automatic eye drop spraying device

By using a closed-loop control system that monitors the eyelids with infrared light and an automatic medication spraying device, the problem of inaccurate medication spraying in existing technologies has been solved, achieving precise and efficient eye medication delivery and improving user experience and safety.

CN224975118UActive Publication Date: 2026-11-17彭礼晴
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202521745766.2
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2025-08-15
Publication Date
2026-11-17
Estimated Expiration
2035-08-15

AI Technical Summary

Technical Problem

Existing eye drop delivery devices lack real-time monitoring of the user's eyelid condition, resulting in inaccurate spraying of the medication, significant waste, and a risk of cross-infection. They also have low levels of intelligence and cannot autonomously identify the optimal time for administration.

Method used

It uses an infrared transmitter and receiver to monitor the eyelid status, and automatically triggers the liquid medication spray through a closed-loop control system. Combined with an elastic drug capsule and a micro-motor driven liquid medication spray module, it achieves precise drug administration, and automatically replenishes the liquid medication through a negative pressure self-filling module.

Benefits of technology

It improves the utilization rate of the medicine solution, reduces waste, lowers the risk of cross-infection, and enhances the accuracy and convenience of medication, especially the ease of operation for special populations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN224975118U_ABST
    Figure CN224975118U_ABST
Patent Text Reader

Abstract

This utility model relates to an automatic eye drop spraying device, comprising: a periocular fitting bracket, an infrared transmitter, an infrared receiver, a liquid spraying module, and a control module. The infrared transmitter and receiver are positioned on opposite sides of the eye in a left-right direction and corresponding to the eyelid opening and closing area in a front-back direction, allowing or blocking infrared rays transmitted from the transmitter to the receiver via eyelid opening and closing. The control module triggers the liquid spraying module to spray liquid eye drops based on changes in the infrared signal received by the receiver. This automatic eye drop spraying device aims to improve the accuracy and convenience of medication administration by introducing a real-time monitoring mechanism for eyelid status, establishing a reliable automatic triggering structure, and ultimately contributing to improved treatment efficacy and patient experience.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This utility model relates to the field of ophthalmic medical device technology, and in particular to an automatic eye drop spraying device. Background Technology

[0002] Eye drops are one of the most commonly used drug formulations in the treatment of ophthalmic diseases, and the effectiveness of their delivery method directly affects the treatment outcome. Currently, eye drop delivery mainly relies on manual operation or some basic electric assistive devices, but these methods generally have inherent limitations. The most traditional method of manually instilling eye drops requires the user to have good hand-eye coordination; however, even normal adults often experience hand tremors, involuntary blinking reflexes, or difficulty accurately aiming at the conjunctival sac, resulting in most of the medication being lost outside the eye, causing significant waste and increasing the risk of cross-infection from the bottle opening touching the eye.

[0003] To address the difficulties of manual operation, some electric eye drops have emerged on the market. These devices typically use a motor-driven pump to spray the medication at a fixed dose and pressure, thus mitigating issues like shaky hands and inaccurate dosage to some extent. However, the level of intelligence in existing electric eye drops is generally low, with triggering mechanisms mostly consisting of simple manual buttons or timers. This "open-loop" control logic means the device itself cannot sense the user's actual state; it cannot determine whether the user's eyes are open or closed. Therefore, the user still needs to strive to keep their eyes open at the moment of pressing the button or waiting for the timer to trigger, which does not fundamentally eliminate the high dependence on the user's subjective cooperation. In actual use, the user may trigger the spray when the eyelids are closed due to nervousness or inaccurate timing, resulting in medication being sprayed onto the eyelids, leading to medication failure and waste.

[0004] Clearly, the core flaw in existing technologies lies in the lack of a "perception-decision" link that effectively links the device's actions with the user's physiological state. Whether it's a manual eye dropper or a simple electric one, the responsibility for determining the optimal drug delivery time rests entirely with the user, without providing any technological means to assist or replace this crucial judgment. Therefore, designing a device that can autonomously recognize the opening and closing state of the user's eyelids and intelligently and automatically trigger drug delivery based on this, thereby achieving truly precise, efficient, and worry-free automated eye drop delivery, is a pressing technical problem that needs to be solved in this field. Utility Model Content

[0005] To address the problems existing in the prior art, this utility model provides an automatic eye drop spraying device. By introducing a mechanism for real-time monitoring of eyelid status, it aims to establish a reliable automatic triggering spraying structure, thereby improving the accuracy and convenience of medication administration and ultimately enhancing treatment efficacy and the patient's medication experience.

[0006] This invention relates to an automatic eye drop spraying device, comprising a periorbital fitting bracket, an eyelid state monitoring module, a drop spraying module, and a control module. The periorbital fitting bracket is the basic supporting structure of the entire device, designed to allow users to stably wear it around the eyes and provide a fixed working platform for other functional modules. The eyelid state monitoring module consists of an infrared transmitter and an infrared receiver, which are spaced apart and mounted on the periorbital fitting bracket. This arrangement allows the infrared transmitter to emit a beam of infrared light to the infrared receiver, forming a fixed monitoring optical path. The drop spraying module is also mounted on the periorbital fitting bracket and has a spray nozzle facing the user's eyeball to perform the final drop spraying action. The control module, as the core of the system, is electrically connected to the infrared receiver in the eyelid state monitoring module and the drop spraying module, responsible for receiving signals and issuing control commands. In terms of specific structural layout, after the device is worn, the infrared transmitter and infrared receiver are located on opposite sides of the eyeball in the left-right direction, such as the nasal side and the temporal side. Optionally, the infrared transmitter and the infrared receiver are symmetrically positioned on the nasal and temporal sides of the periorbital adapter. Simultaneously, in the anterior-posterior direction of the human body, the monitoring light path formed by the two passes precisely through the area where the eyelids can move. This spatial configuration is key to achieving the core function of this invention: when the user's eyelids are closed or partially closed, the eyelid tissue physically blocks the monitoring light path, causing the infrared receiver to be unable to receive or only receive attenuated infrared signals; conversely, when the user's eyelids are fully open, the light path is unobstructed, and the infrared receiver can stably receive infrared signals from the transmitter. Based on the cooperative relationship formed by the above structure, the working process of the device is established. The control module continuously monitors the output signal of the infrared receiver. When the signal strength changes significantly, for example, jumping from a low intensity value (eyelid closed, light path blocked) to a high intensity value, or stabilizing above a certain threshold from a high intensity value (eyelid open, light path unobstructed), the control module determines, according to preset logic, that the user's eyelids are in an open state suitable for drug administration. Once the condition is met, the control module immediately sends a trigger command to the medication spraying module, driving it to spray a predetermined dose of medication onto the user's eyes. In summary, this invention, by constructing a closed-loop control system consisting of an eyelid state monitoring module, a control module, and a medication spraying module, achieves autonomous perception and response of the device to the user's physiological state. Its purpose is to provide an eye drop spraying device capable of intelligently identifying the timing of medication administration and automatically administering the medication.

[0007] Optionally, the infrared receiver and infrared transmitter are positioned at the corner of the periorbital fitting and are adapted to be close to the temporal region of the human eye; wherein, the infrared transmitter emits infrared light to the cornea of ​​the human eye, and the infrared receiver receives the infrared light signal reflected back from the cornea of ​​the human eye.

[0008] Furthermore, the liquid injection module includes an elastic drug capsule and a squeezing drive mechanism for applying or releasing pressure to the elastic drug capsule. It can be understood that in this design, the elastic drug capsule, as a variable-volume liquid storage and release unit, relies on the resilience of its material to achieve its function. The squeezing drive mechanism, as a power actuation component, applies external physical pressure to the elastic drug capsule, reducing its volume and thus squeezing the internal liquid outwards. When the external pressure is released by the mechanism, the elastic drug capsule recovers its original shape due to its material elasticity, and its internal volume increases accordingly. Through this structure, on the one hand, forced discharge of the liquid is achieved through mechanical squeezing. Compared to gravity dripping or manual pressing, its force is controllable and stable, providing a foundation for achieving quantitative liquid injection. On the other hand, utilizing the volume change of the elastic drug capsule due to its shape recovery after pressure release creates a prerequisite for subsequently constructing an automatic liquid replenishment system that requires no additional power source.

[0009] Furthermore, the compression drive mechanism includes a micro motor, a gear set connected to the output shaft of the micro motor, and a compression arm driven by the gear set. The outer wall of the elastic drug capsule is located on the movement path of the compression arm, so that the elastic drug capsule is compressed by the driven compression arm. It can be understood that this scheme establishes a clear power transmission and execution chain: the electrical signal from the control module drives the micro motor to rotate, its rotation is decelerated and torque increased through the gear set, and then drives the compression arm to perform precise displacement movement, ultimately completing one compression and release cycle on the elastic drug capsule. Using a micro motor as the power source allows the magnitude and duration of the driving force to be precisely controlled by electrical signals. The introduction of the gear set effectively converts the high-speed, low-torque characteristics of the micro motor into the low-speed, high-torque action required by the compression arm, ensuring sufficient and stable force to overcome the viscous resistance of the drug liquid and completely compress the elastic drug capsule, thereby ensuring consistent force and stroke height for each injection action. This electromechanical transmission structure accurately converts the digital signals from the control module into repeatable mechanical actions, directly ensuring the stability and accuracy of the drug liquid dosage for each injection, which is a key technical guarantee for achieving quantitative drug administration.

[0010] Furthermore, the outlet of the elastic capsule is connected to a microcatheter, and the end of the microcatheter is equipped with a nozzle serving as the spray nozzle. It can be understood that this structure is designed to guide and process the extruded medication. Specifically, the microcatheter precisely guides the medication from the capsule inside the device to the spray point near the user's eye; its small inner diameter helps maintain medication pressure and flow rate. The nozzle at the end is a core component for improving user experience and medication efficiency.

[0011] Furthermore, a one-way valve is provided between the outlet of the elastic drug capsule and the microcatheter. It is understood that the structural characteristic of the one-way valve is that it only allows fluid to flow in one direction. When the squeezing arm presses the elastic drug capsule, the one-way valve opens, allowing the liquid to flow smoothly to the nozzle. When the squeezing pressure is released and the elastic drug capsule rebounds, generating negative pressure, the one-way valve immediately closes, effectively preventing air from being drawn back into the elastic drug capsule from the outside through the nozzle and microcatheter. This setting plays a crucial role, ensuring that when the drug capsule rebounds and generates negative pressure, this negative pressure acts entirely on the replenishment channel of the liquid, rather than being offset by air drawn in from the spray outlet. Therefore, this one-way valve not only ensures the directional output of the liquid during spraying and prevents backflow, but also provides an indispensable fluid control basis for the subsequent negative pressure self-charging function, ensuring the efficiency and reliability of the self-charging process.

[0012] Furthermore, it also includes a negative pressure self-filling module, which comprises a medicine storage bottle and a flexible hose connecting the medicine storage bottle and the elastic drug capsule. It can be understood that after a single injection is completed and the squeezing arm retracts, the elastic drug capsule returns to its original shape due to its elasticity, increasing in volume and generating negative pressure. Since the one-way valve at the outlet is closed, this negative pressure acts on the liquid medicine in the medicine storage bottle through the flexible hose, automatically drawing it into the elastic drug capsule until the capsule is full. This process fully utilizes the potential energy released by the elastic element after the injection action, requiring no additional pump or power device. The resulting technical effect is significant: it seamlessly integrates the liquid medicine replenishment process into each injection cycle, achieving fully automatic and instantaneous replenishment. Users do not need to manually fill or replace the drug capsule, supporting long-term, high-frequency continuous medication, greatly simplifying the operation process, improving the automation level and ease of use of the device, thereby improving patient compliance for those requiring long-term medication.

[0013] Furthermore, the infrared emitter emits light with a wavelength of 800-1000nm and a power output not exceeding 5mW. It is understood that limiting the wavelength to the near-infrared band of 800-1000nm is because light in this band is invisible to the human eye. When used for eye monitoring, it will not interfere with the user's vision or cause discomfort, ensuring a seamless monitoring process. Strictly controlling the emission power to no more than 5mW is based on considerations of eye safety according to relevant international safety standards (such as the regulations for Class 1 laser products in IEC 60825-1). This low power level ensures that even if the infrared beam acts on the eye area for a prolonged period at close range, its energy is far below the threshold that could potentially damage eye tissue. Therefore, this technical solution, through the precise selection and control of the light source parameters, fundamentally guarantees the biosafety of the device during long-term use, resolving users' concerns about potential safety hazards from light irradiation of the eyes.

[0014] Furthermore, the control module includes a microcontroller electrically connected to the infrared receiver and the drug injection module. It can be understood that the microcontroller processes the real-time signal from the infrared receiver, performs rapid threshold comparison and judgment, and accurately generates the pulse width modulation (PWM) signal required to control the micro-motor, thereby achieving precise control of the injection dosage. Simultaneously, the microcontroller's internal resources also support timing, storage, and other functions, providing computational support for implementing more advanced software functions such as safety locking.

[0015] Furthermore, the infrared emitter and the infrared receiver are symmetrically positioned on the nasal and temporal sides of the periorbital fitting bracket.

[0016] Understandably, the structural layout of this design allows the infrared beam to traverse the area in front of the user's cornea horizontally. When the user's eyelids are fully open, the edges of the upper and lower eyelids are outside this horizontal light path, ensuring unobstructed access. However, when the user's eyelids are closed or not fully open, the upper or lower eyelid directly blocks the light path. Compared to other possible layouts (such as an up-and-down arrangement), this lateral, opposing beam arrangement maximizes the use of eyelid opening and closing movements to switch the light path "on" and "off," resulting in a highly significant difference in signal strength received by the infrared receiver between open and closed eyelid states. This high signal-to-noise ratio signal variation greatly reduces the misjudgment rate of the control module, ensuring that the system can accurately and reliably identify the truly suitable "fully open eye" state for drug administration. This is the core prerequisite for the entire device to achieve precise triggering and avoid drug waste.

[0017] Furthermore, the control module also includes a safety locking module embedded in the microcontroller's firmware. This module records the timestamp of each trigger and sets a preset safety threshold. This solution adds an active safety layer to the device through software algorithms. After each successful spray trigger, the microcontroller records the current time. When the trigger condition is met again, it first calculates the time interval between the current trigger and the previously recorded timestamp and compares it to a preset safety threshold (e.g., 3 seconds). If the interval is less than this threshold, the system determines it as an abnormal, excessively frequent operation and actively suspends the spraying function until the safety time interval condition is met. This design effectively prevents continuous spraying within a short period due to user error, children playing with the device, or device malfunction, thus avoiding the potential risk of excessive medication use. Through intelligent logical judgment, it adds an extra layer of protection for medication safety, making the device more compliant with the stringent safety requirements of medical devices while achieving automation.

[0018] This invention relates to an automatic eye drop dispensing device that directly links the triggering conditions for medication dispensing to the user's actual eye-opening action, ensuring that each medication administration is performed at the optimal time when the conjunctival sac is effectively exposed. This intelligent closed-loop control method fundamentally avoids accidental triggering when the user's eyes are closed or not ready, thereby greatly improving medication utilization and reducing waste caused by improper operation. Simultaneously, because the medication administration process is automatically completed based on objective physiological signals, it reduces the operational burden on users, especially those with hand disabilities or difficulty aiming, improving the accuracy and convenience of medication administration, ultimately contributing to improved treatment outcomes and the patient's medication experience. Attached Figure Description

[0019] To more clearly illustrate the technical solutions in this utility model or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this utility model. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0020] Figure 1 This is an overall structural diagram of the present invention;

[0021] Figure 2 This is a diagram of the control module of this utility model;

[0022] Figure 3 This is a schematic diagram of the detection principle of this utility model (when the eyelids are open, the infrared light is not blocked by the eyelids, and the receiver can receive the infrared light from the infrared emitter).

[0023] Figure 4 This is a schematic diagram of the detection principle of this utility model (when the eyelids are closed, the infrared light is blocked by the eyelids, and the receiver cannot receive the infrared light from the infrared emitter).

[0024] Figure 5 This is a schematic diagram of the internal structure of the liquid injection module of this utility model;

[0025] Figure 6 This is a structural schematic diagram of Embodiment 3 of this utility model.

[0026] Figure label:

[0027] 130. Periocular fitting support;

[0028] 100. Eyelid status monitoring module; 110. Infrared transmitter; 120. Infrared receiver;

[0029] 200. Control module; 210. Microcontroller;

[0030] 300. Liquid injection module; 310. Micro motor; 311. Gear set; 312. Extrusion arm; 320. Elastic drug capsule; 321. One-way valve; 322. Microcatheter; 323. Nozzle.

[0031] 400. Negative pressure self-charging module; 410. Medicine storage bottle; 411. Flexible hose. Detailed Implementation

[0032] The embodiments of this utility model are described in detail below. Examples of these embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain this utility model, and should not be construed as limiting this utility model. In the description of this utility model, it should be understood that the terms "center," "longitudinal," "lateral," "length," "width," "thickness," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," "clockwise," "counterclockwise," "axial," "radial," "circumferential," etc., indicating the orientation or positional relationship, are based on the orientation or positional relationship shown in the accompanying drawings, and are only for the convenience of describing this utility model and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation, and therefore should not be construed as limiting this utility model.

[0033] Example 1

[0034] Please see Figures 1 to 5 This embodiment provides a detailed structure of an automatic eye drop spraying device. For example... Figure 1As shown, the device comprises an eye-adaptive support 130 that can be worn around the user's eyes, and an eyelid status monitoring module 100, a control module 200, and a medication spraying module 300 fixed to the support. The eye-adaptive support 130 is designed to fit different users' head shapes and facial contours to ensure the stability and comfort of wearing the device.

[0035] The eyelid state monitoring module 100 is the core of the intelligent triggering system, comprising an infrared emitter 110 and an infrared receiver 120. In this embodiment, the infrared emitter 110 and infrared receiver 120 are symmetrically positioned on the periocular fitting bracket 130, corresponding to the user's nasal and temporal sides respectively, so that they are distributed on opposite sides of the eye in the left-right direction. This arrangement allows the beam emitted by the infrared emitter 110 to pass laterally through the space in front of the user's cornea. Figure 3 and Figure 4 As shown, when the user's eyelids are fully open, the light path is unobstructed, and the infrared receiver 120 can stably receive the infrared signal. However, when the user's eyelids are closed or not fully open, the upper and lower eyelids block the light path, causing a sharp attenuation of the signal strength received by the infrared receiver 120. This arrangement utilizes the opening and closing of the eyelids to switch the light path on and off, generating a high signal-to-noise ratio signal change, providing a reliable basis for subsequent accurate judgment. To ensure safety, the infrared transmitter 110 preferably uses a near-infrared light source with an emission wavelength of 800-1000nm and an emission power not exceeding 5mW. This parameter range complies with relevant safety standards, is harmless to the human eye, and is invisible light, so it will not interfere with the user's vision.

[0036] The control module 200 serves as the control center of the device, and its core circuitry consists of a microcontroller 210, such as... Figure 2 As shown. The input of the microcontroller 210 is electrically connected to the infrared receiver 120, and its output is electrically connected to the drive component within the drug injection module 300. The microcontroller 210 is configured to monitor the signal level of the infrared receiver 120 in real time. When the detected signal strength is below a preset threshold, for example, light intensity below 200 Lux, the microcontroller 210 determines that the user's eyelids are fully open, which is the optimal time for drug administration. Once the determination condition is met, the control module 200 immediately drives the drug injection module 300 to perform the injection action.

[0037] Please see Figure 5The internal structure of the liquid injection module 300 enables precise liquid injection. It includes an elastic drug capsule 320 made of medical-grade silicone and a compression drive mechanism for applying and releasing pressure on it. This compression drive mechanism specifically includes a micro motor 310, a gear set 311 connected to the motor's output shaft, and a compression arm 312 driven by the gear set 311. The elastic drug capsule 320 is positioned along the movement path of the compression arm 312. When the control module 200 issues a command, the micro motor 310 (e.g., a JGA25-370 geared motor) starts, its rotational motion is decelerated and increased in torque via the gear set 311, and drives the compression arm 312 in a precise circular motion. During this circular motion, the compression arm 312 applies pressure to the elastic drug capsule 320, stably compressing it. This mechanical structure precisely converts electrical signals into repeatable circular mechanical motion, ensuring consistency in the stroke and force of each compression action. The outlet of the elastic capsule 320 is connected to a microcatheter 322, through which the medication is extruded under pressure. A one-way valve 321 is installed between the outlet of the elastic capsule 320 and the microcatheter 322 to ensure that the medication flows only from the capsule to the catheter and cannot flow back. A nozzle 323, serving as a spray port, is located at the end of the microcatheter 322, facilitating the spraying of the medication onto the ocular surface. The entire spraying process is precisely controlled by a pulse width modulation (PWM) signal output from the control module 200. For example, a PWM signal with a duration of 0.3 seconds and a duty cycle of 80% drives a micromotor 310 to complete one extrusion action, thereby achieving stable control of the single spray dose (e.g., 25 ± 1 μl).

[0038] The device in this embodiment also includes a negative pressure self-filling module 400, which cleverly utilizes the mechanical energy after the spray cycle. It includes a 5ml medicine bottle 410 and a flexible hose 411 connecting the medicine bottle 410 to the inlet of the elastic medicine sac 320. After one spray cycle, the control module 200 drives the micro motor 310 to reset, causing the squeezing arm 312 to retract from the elastic medicine sac 320. Because the elastic medicine sac 320 has high resilience, it quickly returns to its original shape after the pressure is released, causing the volume inside the sac to increase and create negative pressure. At this time, because the one-way valve 321 at the outlet prevents air from being drawn back from the nozzle, this negative pressure acts on the medicine bottle 410 through the flexible hose 411, automatically drawing the medicine from the bottle into the elastic medicine sac 320 until it is full, preparing for the next spray. This process requires no additional power, achieving automatic and efficient replenishment of the medicine, greatly facilitating users who need long-term, high-frequency medication.

[0039] In addition, to ensure medication safety, a safety lock module is embedded in the firmware of the control module 200. This module is implemented through the timer function of the microcontroller 210, which records the timestamp of each successful trigger of the spray. If the system detects that the interval between two consecutive triggers is less than a preset safety threshold T (e.g., 3 seconds), the system will pause the response to the trigger signal and will remind the user through methods such as flashing LEDs or beeping a buzzer, until normal operation resumes after the safety time interval has elapsed. This function effectively prevents overdose of medication due to misoperation or accidental situations.

[0040] Example 2

[0041] This embodiment, based on embodiment 1, further integrates intelligent interactive functions and an optimized consumables management solution, aiming to improve user experience and data management capabilities.

[0042] In this embodiment, a low-power Bluetooth module is additionally integrated into the hardware circuit of the control module 200. This Bluetooth module enables the device to establish a wireless connection with the user's smartphone or other smart terminal devices. By installing a companion application (APP) on the smartphone, the user can achieve more personalized settings and functions. For example, the user can easily set the safety threshold T in the safety lock module through the APP interface to adapt to different treatment plans or personal usage habits. At the same time, the APP can record and display detailed medication history data, including medication time, frequency, etc., to facilitate users or doctors to track the treatment progress. The APP can also provide reminders for low battery or low medication volume in the medicine bottle 410 to ensure the continuous availability of the device.

[0043] To further enhance ease of use and hygiene, the negative pressure self-filling module 400 in this embodiment adopts a quick-replacement design. Specifically, the medicine storage bottle 410 is designed as an independent, pre-sealed medicine container. This medicine container is connected to the main body of the device via a quick-release mechanism. When the medicine is depleted, the user does not need to perform cumbersome refilling operations; they can simply press the release button to remove the old medicine container and replace it with a new, sterile, pre-sealed medicine container. The entire replacement process is quick and easy, while also avoiding the risk of contamination of the medicine during the refilling process.

[0044] To meet the portability requirements of the device, this embodiment incorporates a rechargeable lithium battery as its power source and charges via a universal Type-C interface, thereby improving the device's battery life and charging convenience. The remaining structure and operating principles, such as eyelid status monitoring, negative pressure self-charging mechanism, and quantitative injection control, are the same as described in Embodiment 1.

[0045] Example 3

[0046] This embodiment is similar to Embodiment 1, except that, as follows: Figure 6 As shown, the infrared receiver 120 and the infrared transmitter 110 are positioned at the corner of the periorbital adapter 130 and are adapted to be close to the front of the temporal region of the human eye; wherein, the infrared transmitter 110 emits infrared light to the cornea of ​​the human eyeball, and the infrared receiver 120 receives the infrared light signal reflected back from the cornea of ​​the human eyeball.

[0047] During operation, the infrared emitter 110 emits infrared light of a predetermined intensity toward the corneal surface of the human eye. This infrared light is reflected upon impact with the corneal surface, and the infrared receiver 120, located on the same side, receives the infrared light signal reflected from the cornea or eyelid surface. The physical principle of this monitoring method lies in the significant difference in optical reflectivity between the surface characteristics of the cornea when the eyes are open and the surface characteristics of the eyelid skin when the eyes are closed. When the eyes are open or not fully closed, the corneal surface reflects most of the infrared light to the infrared receiver 120, resulting in a strong light signal. When the eyelids are closed, the skin surface absorbs or diffusely reflects most of the infrared light, causing a significant decrease in the signal strength received by the infrared receiver 120. The control module 200 determines the eyelid closure state based on the changes in the signal strength data from the infrared receiver 120.

[0048] Therefore, during use, when the human eye is closed, the infrared light emitted by the infrared emitter 110 to the cornea is blocked by the eyelid, resulting in a significant reduction in the signal strength received by the infrared receiver 120. At this time, the control module 200 can determine that the human eye is closed and will not trigger the medication spraying module 300 to spray medication into the eye. Conversely, when the human eye is open, the infrared light emitted by the infrared emitter 110 to the cornea is not blocked by the eyelid, and the corneal surface reflects most of the infrared light to the infrared receiver 120, resulting in a stronger light signal received by the receiver 120. At this time, the control module 200 can determine that the human eye is open and can normally trigger the medication spraying module 300 to spray medication into the eye.

[0049] The parts not mentioned in this embodiment are the same as in Embodiment 1, so they will not be described again.

[0050] The above description is only a preferred embodiment of the present utility model and is not intended to limit the technical solution of the present utility model. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present utility model should be included within the protection scope of the present utility model.

Claims

1. An automatic eye drop spraying device, characterized in that, include: Periorbital fitting bracket (130) for wearing on the human eye area; The eyelid status monitoring module (100) includes an infrared transmitter (110) and an infrared receiver (120), wherein the infrared transmitter (110) and the infrared receiver (120) are spaced apart on the periorbital fitting bracket (130), and the infrared transmitter (110) sends infrared rays to the infrared receiver (120); The liquid injection module (300) is mounted on the periorbital adapter bracket (130) and has a spray nozzle facing the human eye; The control module (200) is electrically connected to the infrared receiver (120) of the eyelid state monitoring module (100) and the medicine spraying module (300); in, The control module (200) triggers the liquid spraying module (300) to spray liquid medicine onto the human eye based on the change in the infrared signal received by the infrared receiver (120).

2. The automatic eye drop spraying device according to claim 1, characterized in that, The infrared emitter (110) and infrared receiver (120) are distributed on opposite sides of the human eye in the left-right direction of the human body and correspond to the eyelid opening and closing area of ​​the human eye in the front-back direction of the human body, so as to allow or block the infrared rays sent by the infrared emitter (110) to the infrared receiver (120) through the opening and closing action of the eyelid. The infrared transmitter (110) and the infrared receiver (120) are symmetrically arranged on the nasal and temporal sides of the periorbital fitting bracket (130).

3. The automatic eye drop spraying device according to claim 1, characterized in that: The infrared receiver (120) and infrared transmitter (110) are located at the corners of the periorbital adapter (130) and are adapted to be close to the front of the temporal region of the human eye. In this process, infrared light is emitted to the cornea of ​​the human eye through the infrared emitter (110), and the infrared light signal reflected back from the cornea of ​​the human eye is received through the infrared receiver (120).

4. The automatic eye drop spraying device according to claim 1, characterized in that, The liquid injection module (300) includes an elastic sac (320) and a compression drive mechanism for applying or releasing pressure to the elastic sac (320).

5. The automatic eye drop spraying device according to claim 4, characterized in that, The extrusion drive mechanism includes a micro motor (310), a gear set (311) that is connected to the output shaft of the micro motor (310), and an extrusion arm (312) driven by the gear set (311). The outer wall of the elastic drug capsule (320) is located on the movement path of the extrusion arm (312) so that the elastic drug capsule (320) is extruded by the driven extrusion arm (312).

6. The automatic eye drop spraying device according to claim 4, characterized in that, The outlet of the elastic drug capsule (320) is connected to a microcatheter (322), and the end of the microcatheter (322) is provided with a nozzle (323) serving as the spray port.

7. The automatic eye drop spraying device according to claim 6, characterized in that, A one-way valve (321) is provided between the outlet of the elastic drug capsule (320) and the microcatheter (322).

8. The automatic eye drop spraying device according to claim 4, characterized in that, It also includes a negative pressure self-charging module (400), which includes a medicine storage bottle (410) and a flexible tube (411) for connecting the medicine storage bottle (410) and the elastic medicine bag (320).

9. The automatic eye drop spraying device according to claim 1, characterized in that, The infrared emitter (110) has an emission wavelength of 800-1000nm and an emission power of no more than 5mW.

10. The automatic eye drop spraying device according to claim 1, characterized in that, The control module (200) includes a microcontroller (210) which is electrically connected to the infrared receiver (120) and the liquid injection module (300).